Skip to main content
. Author manuscript; available in PMC: 2013 Aug 16.
Published in final edited form as: Cancer Res. 2013 Mar 27;73(7):2159–2169. doi: 10.1158/0008-5472.CAN-12-1962

Figure 1.

Figure 1

Nuclear SOX9 expression in esophageal adenocarcinoma tumor tissues correlates with poorer clinical outcome. A, tissue microarray slides were immunohistochemically stained using SOX9 antibody as described in Materials and Methods. A, representative staining of SOX9 was shown in normal esophagus and esophageal adenocarcinoma with well-, moderate-, and poorly differentiated tumors. B, nuclear SOX9 staining in different stages of esophageal adenocarcinoma tumor tissues. The tumors were categorized into SOX9 low and SOX9 high based on the scoring of nuclear staining in tumor cells and staining intensity. C, Kaplan–Meier survival analysis indicated that high levels of nuclear SOX9 expression are associated with poor survival in esophageal adenocarcinoma patients (P < 0.05).